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State-of-the-art next-generation-sequencing technologies can facilitate in-depth explorations of the human genome by investigating
both common and rare variants. For the identification of genetic factors that are associated with disease risk or other complex pheno-
types, methods have been proposed for jointly analyzing variants in a set (e.g., all coding SNPs in a gene). Variants in a properly defined
set could be associated with risk or phenotype in a concerted fashion, and by accumulating information from them, one can improve
power to detect genetic risk factors. Many set-basedmethods in the literature are based on statistics that can be written as the summation
of variant statistics. Here, we propose taking the summation of the exponential of variant statistics as the set summary for association
testing. From both Bayesian and frequentist perspectives, we provide theoretical justification for taking the sum of the exponential of
variant statistics because it is particularly powerful for sparse alternatives—that is, compared with the large number of variants being
tested in a set, only relatively few variants are associated with disease risk—a distinctive feature of genetic data. We applied the exponen-
tial combination gene-based test to a sequencing study in anticancer pharmacogenomics and uncoveredmechanistic insights into genes
and pathways related to chemotherapeutic susceptibility for an important class of oncologic drugs.Introduction
Advances in high-throughput arrays have made feasible
the genotyping of hundreds of thousands to millions of
SNPs for a large number of subjects.1 As a result, genome-
wide association studies (GWASs) have flourished in the
past decade, and thousands of SNPs have been successfully
associated with complex disease traits.2 Despite the success
of GWASs, a large proportion of genetic variation under-
lying disease risk remains unidentified.3 One possibility
is that many of the causal variants are rare in the popula-
tion and are therefore poorly captured by GWASs. As
state-of-the-art technology, next-generation sequencing
provides a more accurate and comprehensive measure-
ment of genetic variation, especially for the rare part of
the frequency spectrum.4 Rare variants appear infre-
quently in the sampled subjects, making them less likely
(unless the sample size is very large) to be detected with
single-SNP inference. Moreover, as millions of variants
are tested for association, one needs to apply a stringent
multiple-testing adjustment. Therefore, in current se-
quencing studies, power for detecting risk-associated rare
variants is a major concern.
For improving the power for detecting genetic risk
factors, a natural approach in sequencing studies is to
analyze sets of genetic variants.5–11 The rationale is that
by accumulating information on functionally related
variants, one can gain power to detect associations. In
addition, the number of tests is greatly reduced, and
the significance criterion is relaxed. In the set-based
analysis, a set is often defined by functional ‘‘units,’’ for
example, a gene5 or a pathway.12 To illustrate the con-
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Various methods have been proposed for jointly
analyzing multiple variants in a gene. In the cohort allelic
sums test,5 the combined-multivariate-and-collapsing
method,6 and the weighted sum test by Madsen and
Browning (designated here as the burden test),7 rare-allele
counts of individual variants are collapsed (with weights)
in a gene for cases and are contrasted with those for
controls for the formation of an association statistic. The
C-alpha test10 is based on the sum of variant statistics,
each of which compares the observed and the expected
variance of minor allele frequencies (MAFs) in cases for
a variant in the gene. The C-alpha test is robust to the
direction of association effects. Wu et al. (2011)11 proposed
a weighted kernel regression approach (sequence kernel
association test [SKAT]) that upweighs rare variants. Under
certain conditions, such as assigning equal weights to vari-
ants regardless of MAF and with no covariates, SKAT and
some other regression-based tests8,9 are almost equivalent
to the C-alpha test. We mainly discuss the burden test
and the C-alpha test in this work as examples of set-based
tests. In large samples, the burden test can be approxi-
mated by a linear combination of normal statistics,
whereas the C-alpha test can be approximated by a linear
combination of chi-square statistics. They represent two
classes of set-based tests.
Set-based methods can be viewed as ways of combining
individual statistics, i.e., of determining whether an effect
is present in at least one of the variants in the set. Many
set-based test statistics can, in fact, be represented as the
linear combination of variant statistics. Linear combination
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the most powerful test for testing against simple alternative
hypotheses.13 In the context of case-control sequencing
studies, linear combination is powerful if the goal is to test
whether odds ratios are equal to 1 for all variants in a gene,
as opposed to whether odds ratios are equal to some given
value, say 1.2. However, linear combination is no longer
the most powerful test if the alternative is composite, for
example, not all odds ratios are equal to one. In addition to
linear-combination procedures, other methods for com-
bining individual test statistics in a set-based test are also
proposed and discussed. Fisher’s and Tippett’s methods are
widely used as combination tests.14 Fisher’s method rejects
large values of 2P logðpiÞ; where pi is the p value corre-
sponding to the individual statistic Zi.
15 Tippett’s method
rejects low values of the minimum of p values, minðpiÞ.14
These two combination procedures are nonparametric in the
sense that they are based on individual p values in a set
regardless of the distributional form of the test statistics.
Some other nonparametric set-basedmethods have been
proposed in the context of genetics or expression studies.
For example, Zaykin et al. (2002)16 proposed a truncated
product method for combining p values in a set. Zaykin
et al. (2007)17 proposed a soft-threshold method with
a test statistic as the sum of inverse gamma transformation
of p values in a set. Yu et al. (2009)18 and Biernacka et al.
(2012)19 extended the p value combination methods to
gene-set or pathway analysis in association studies. These
methods share a similar idea to our proposed method:
when only a small number of statistics in a set are from
the alternative, linear combination or Fisher’s method
might not be powerful, and when more than one statistic
in a set is from the alternative, Tippett’s method is also
not optimal. In contrast to our proposed method, these
methods16–19 are based on combining individual p values
instead of test statistics in a set. In sequencing studies
that involve a lot of rare variants, individual p values for
rare variants might be unreliable, and set-based tests based
on individual p values can result in loss of power, espe-
cially when rare variants are more strongly associated
with disease risk than common variants.
For combining multiple one-sided normal statistics, van
Zwet and Oosterhoff (1967)20 proposed the statisticP
expðwiZiÞ, where wi is the weight and Zi is normally
distributed. Koziol and Perlman (1978)21 proposed the
statistic
P
expðwiZiÞ for combining independent chi-
square statistics. Both take the sum of the exponential
of individual statistics as set statistics. In contrast with
Fisher’s, Tippett’s, and other nonparametric methods,
linear combination and the sum of exponential of statistics
are parametric because they are derived from the density
functions of statistics from exponential families.
In this work, we propose an exponential-combination
(EC) framework for set-based association tests in sequenc-
ing studies. EC is not just one test statistic but is, rather,
a general procedure that can be used for combining
individual variant statistics for performing set-based anal-
ysis. The proposed EC procedure improves power under978 The American Journal of Human Genetics 91, 977–986, Decemba natural class of alternatives for set-based tests in
sequencing studies. Genetic data, particularly sequencing
data, have distinctive features that can guide us in finding
powerful combination procedures. Specifically, among
tens of millions of known variants, only a very small
proportion is related to disease risk for any particular
disease. If a gene harbors k variants and k0 of them are truly
associated with disease risk, it is likely that k0  k, particu-
larly if k is large. Thus, instead of testing against a generic
alternative (e.g., when at least one SNP is associated), a
more realistic composite alternative hypothesis is to test
whether only a small number among all variants have non-
zero effects while all the other variants have zero effects.
We term this kind of alternative a sparse alternative.
EC accounts for these distinctive features of sequencing
studies. In the following sections, we derive the EC statistic
against a sparse alternative from both Bayesian and fre-
quentist perspectives. With simulated examples and an
application to sequencing-based data in pharmacogenom-
ics, we show that EC is more powerful than other combina-
tionmethods for set-based tests when only a small number
of variant statistics are truly from the alternative.
Material and Methods
We denote with k the number of variants in a set under investiga-
tion. Many commonly used set-based test statistics can be written
as a linear combination of variant statistics, i.e., Z ¼Pki¼1piZi,
where pi ðpiR0Þ is the weight and Zi is the statistic of the ith
variant. When only a small number of variant statistics are from
the alternative, a more powerful combination procedure exists.
This powerful combination is to take the sum of the exponential
of squared variant statistics, Z ¼Pki¼1pi expðwiZ2i Þ if Zi is (approx-
imately) normally distributed, or the sum of the exponential of
variant statistics, Z ¼Pki¼1pi expðwiZiÞ if Zi is (approximately)
chi-square distributed. Here, wi ðwiR0Þ is the weight on the expo-
nential scale, and pi is the weight on the linear scale for the indi-
vidual variant statistic Zi. We suggest the use of wi ¼ 1=2 and
pi ¼ 1 as the default.
The Bayesian Interpretation of EC
The distinctive feature of genetic data—sparse association—could
be modeled in the prior of Bayesian inference. Suppose that the
variant statistics Z1;.;Zk are independently distributed and that
each has the density function f ðzi; qiÞ; i ¼ 1;.; k, where qi is the
parameter of interest. To test the null hypothesis, H0 : qi%0 c i,
against the alternative hypothesis, H1: at least one qi > 0, the
Bayes test has the rejection region(
ðz1;.; zkÞ :
Z Yk
i¼1

f ðzi; qiÞ
f ðzi;0Þ

dfðq1;.; qkÞ > c
)
; (Equation 1)
where f represents the prior probability distribution of ðq1;.; qkÞ
over the alternative space U and c is chosen for achieving the over-
all significance level a. The Bayes test minimizes the Bayes risk and
is most powerful if the prior is correctly specified.
Different priors yield different Bayes tests, and we consider here
two classes of prior distributions. Under the alternative with
a ‘‘class I prior,’’ qi’s vary independently over the alternative space
U, and each qi has marginal prior fiðqiÞ. When Zi’s are normally orer 7, 2012
chi-square distributed and have marginal conjugate priors for the
qi’s, the integral in Equation 1 reduces to rejecting large
Pk
i¼1piZi,
where pi’s are the weights and are functions of fi’s.
21 Therefore,
the linear-combination test is the Bayes test under the class I prior.
For example, when each variant in a gene is independently associ-
ated with disease risk with a nonzero log odds ratio, the linear
combination of variant statistics is powerful.
Now consider another type of prior, ‘‘class II prior,’’ where only
one qis0 and all other qj’s ¼ 0 ðisjÞ. The prior puts positive prob-
ability hi at the coordinate axis ð0;.; qi;.;0Þ in the alternative
space, where
P
ihi ¼ 1. With class II prior, we only consider each
coordinate axis to decide the rejection rule for the Bayes test.
The Bayes test in Equation 1 rejects when the following is large:
X
hi
ZN
N
f ðzi; qiÞ
f ðzi;0Þ fiðqiÞdqi: (Equation 2)
Suppose that each Zi independently follows a normal distribu-
tion with mean qi and unit variance Zi  Nðqi;1Þ. With class II
prior, we have q ¼ ð0;.;0; qi;0;.;0Þ with probability hi under
the alternative, where qi  fiðqiÞ ¼ Nð0; t2i Þ. Here, we choose
Nð0; t2i Þ as the prior for qi because it is the conjugate prior for
the normal distribution and gives an explicit analytic form. This
test can be viewed as a union-intersection test of two one-sided
tests: one is for testing H0 : qi%0 for all i against H1: only one
qi > 0; the other is for testing H0 : qiR0 for all i against H1: only
one qi < 0. The rejection rule in Equation 2 for testing the first
one-sided test is rejecting large values ofX
pi exp

wiZ
2
i

; (Equation 3)
where pifhi and wi ¼ 1=2ð1þ 1=t2i Þ. It is natural to use hi ¼ 1=k.
As the hyperparameter ti becomes large, wi converges to 1/2. On
the basis of a similar derivation, this is also the rejection rule for
the second one-sided test H0 : qiR0 for all i versus H1: only one
qi < 0. Therefore, to combine multiple normal statistics and to
test whether one of them has a nonzero mean, the Bayes test
rejects a large value of the EC of squared normal statistics,P
expð1=2 Z2i Þ.
Consider the sparse alternative that at least one and at most k0
out of k statistics have qi > 0, for which k
0  k. Under this sparse
alternative, the Bayes test is not easily derived and does not have
a simple form. However, this sparse alternative is much closer to
class II priors than to class I priors. Even though EC is not neces-
sarily the Bayes test under general sparse alternatives, it remains
more powerful than linear combination for combining normal
or chi-square statistics.
From a Frequentist Perspective: EC as a Score Test
Interestingly, the same EC procedure can also be derived as the
score test for testing H0 : p ¼ 0 against H1 : p > 0 on the basis of
the profile likelihood f ðzi;.; zkjq1;.; qk; pÞ, where p is the proba-
bility of qi being nonzero. Let X be the number of qi’s that are
nonzero and let X  Bðk; pÞ. The full likelihood is
L ¼ f ðz1;.; zk j pÞ ¼
R
f ðz1;.; zk j xÞf ðx j pÞdx
f
Pk
x¼0
P
ð1Þ; . ;ðkÞ˛L
e
12
Px
i¼1
ðzðiÞqðiÞÞ2
e
12
Pk
i¼xþ1
z2ðiÞ

k
x

pxð1 pÞkx;
where L is composed of all permutations fð1Þ;.; ðkÞg of
the labels for the k variant statistics. For x ¼ 0, we defineP0
i¼1ðzðiÞ  qðiÞÞ2 ¼ 0. For x ¼ k, we define
Pk
i¼kþ1z
2
ðiÞ ¼ 0.The AmericanConsider the score test for testing H0 : p ¼ 0 against H1 : p > 0.
Specifically, at each X ¼ 0;.; k, one can maximize the likelihood
for the nonzero means bqMLEðiÞ ¼ zðiÞ. The resulting profile likelihood
is given by
~Lfe
1
2
Pk
i¼1
z2
i Xk
x¼0
X
ð1Þ; . ;ðkÞ˛L
e
1
2
Px
i¼1
z2ðiÞ

k
x

pxð1 pÞkx:
If we take the derivative of the log profile likelihood with respect
to p, we obtain the following score function:
d log ~L
dp
¼
Pk
x¼0
P
ð1Þ; . ;ðkÞ˛L
e
1
2
Px
i¼1
z2ðiÞ

k
x

pxð1 pÞkx

x
p
 k x
1 p

Pk
x¼0
P
ð1Þ; . ;ðkÞ˛L
e
1
2
Px
i¼1
z2ðiÞ

k
x

pxð1 pÞkx
:
As p/0, only X ¼ 0 and X ¼ 1 contribute to the numerator and
only X ¼ 0 contributes to the denominator, giving the score eval-
uated at null:
lim
p/0
d log ~L
dp
¼ kþ k
Xk
i¼1
e
1
2 z
2
i :
Hence, the score test for testing H0 : p ¼ 0 rejects large values ofPk
i¼1expð1=2 Z2i Þ, which is the same as the Bayesian test derived
under the class II prior.
EC of Chi-Square Statistics
In a related work, Koziol and Perlman (1978)21 discussed
the combination procedures for combining independent chi-
square statistics. In brief, let Zi be chi-square distributed
with degrees of freedom (df) dfi and noncentrality parameter
qi. For testing H0 : q ¼ 0 against H1 :
P
qi > 0 with class II
priors, the prior distribution is that with probability hi, qi is
distributed according to the conjugate prior gamma distribution
fiðqiÞ ¼ ðadfi=2i =Gðdfi=2ÞÞ qdfi=21i expðaiqiÞ; where ai is a hyper-
parameter and all other fjðqjÞ ¼ 0 ðjsiÞ. Under this alternative,
the Bayes test in Equation 2 can be reduced to rejecting large
Xk
i¼1
pi expðwiZiÞ; (Equation 4)
where pifhi and wi ¼ 1=ð2ð2ai þ 1ÞÞ. We use hi ¼ 1=k. When ai is
small, the exponential weight wi also approaches 1/2. The Bayes
test in Equation 4 rejects large
Pk
i¼1expðð1=2ÞZiÞ when each Zi is
1 df chi-square distributed.
Weights
Although the idea of EC is to ‘‘boost’’ the large individual statistics
in a set when only very few are expected to be from the alternative,
how much we should boost is not an arbitrary decision. Large
exponential weights could yield huge combined statistics under
both the null and the alternative, resulting in low power for distin-
guishing the alternative from the null. On the basis of mathemat-
ical derivations, we obtained the exponential weight wi ¼ 1=2
when combining k normal or chi-square statistics for testing
against the most sparse alternative—only one out of k is from
the alternative.When the alternative is less sparse,wi < 1=2might
be slightly more powerful because it puts more weights on statis-
tics other than the largest ones. In general, when multiple stan-
dardized statistics are combined, exponential weights around or
less than 1/2 are appropriate. In Appendix A, we derive the EC
statistics for the burden and the C-alpha tests on the basis of theirJournal of Human Genetics 91, 977–986, December 7, 2012 979
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Figure 1. Boundary of Acceptance Regions of the Four Combi-
nation Procedures
For testing the noncentrality parameters for Z1;Z2  c21,
H0 : q1 ¼ q2 ¼ 0 versus H1 : q1R0 and q2R0 with q1 þ q2 > 0, the
boundaries of acceptance regions of exponential (red solid),
Tippett’s (blue dot-dash), Fisher’s (green dotted), and linear (black
dashed) combination procedures are compared. The size of each
combined test is a ¼ 0.01.respective standardized variant statistics. By standardization, we
implicitly impose the exponential weights that are inversely
proportional to the SD of variant statistics under the null. Because
rare variants have smaller SDs, they are weighted more heavily
than common variants in the EC analyses.
Sequential Precision-Improvement Permutation
for Calculating p Values
As a result of low rare-allele counts in the sample, the individual
variant statistics, Zi’s, do not often follow the standard normal
or chi-square distribution. Even when they do, the EC statistic,Pk
i¼1expðð1=2Þ Z2i Þ for combining normal or
Pk
i¼1expðð1=2Þ ZiÞ
for combining 1 df chi-square statistics, does not have a trivial
distribution. Moreover, the parametric form of the EC statistic
might become intractable when the linkage disequilibrium (LD)
structure among variants is unknown and not easily estimated.
To accurately assess the significance,wepermutedphenotypes to
calculate the p values. To alleviate the computational burden, we
used a sequential precision-improvement permutation algorithm
to calculate set-based p values. Specifically, we first permuted
phenotypes B ¼ 100 times and estimated the p value for each set.
For sets with p values less than 10/B ¼ 0.1, we recalculated their
p values with ten times more permutations (B¼ 1,000) to improve
precision. If any genes still had p values less than 10/B ¼ 0.01,
we recalculated their p values with ten times more permutations
(B ¼ 104). We repeated this procedure until no gene had a p value
with low precision (<10/B) or until the number of permutations
was greater than a certain fixed number, for example, 106.Results
Simulations: Power Comparison with Other
Combination Procedures Combining Two
Chi-square Statistics
Consider a simple scenario: a gene with only two variants.
We first calculated the test statistic for each variant,980 The American Journal of Human Genetics 91, 977–986, DecembZiði ¼ 1;2Þ. Under the null, i.e., if the variant is not risk
associated, Zi follows a chi-square distribution with 1 df
and noncentrality parameter qi ¼ 0. Under the alternative,
qi > 0. To test whether the gene is associated with disease
risk is to test whether either statistic Zi is from the alterna-
tive. We compared the acceptance boundaries (at size a ¼
0.01) of four combination procedures for combining two
chi-square statistics (see Figure 1). The four combination
procedures are: the EC method with gene statisticP2
i¼1expðZi=2Þ, Tippett’s method with gene statistic
mini¼1;2ðpiÞ, where pi is the p value for Zi ði ¼ 1; 2Þ, Fisher’s
method with statistic 2P2i¼1log pi, and the linear-combi-
nation method with gene statistic
P2
i¼1Zi. The linear
combination and Fisher’s combination have smaller accep-
tance regions near the symmetric line z1 ¼ z2 (Figure 1)
and are thus more powerful when both variant statistics
are from the alternative. Exponential and Tippett’s combi-
nations are more powerful near the lines when z1 ¼ 0 or
z2 ¼ 0. They are more powerful when only one variant
statistic is from the alternative. Tippett’s method, however,
has the least power when z1 ¼ z2, whereas EC remains
competitive when z1 ¼ z2.Comparing the Four Combination Procedures on Two
Commonly Used Set-Based Methods in Sequencing
Studies
We simulated data sets with 10,000 variants not associated
with disease risk and 5,000 variants associated with disease
risk. For all 5,000 risk-associated variants, we simulated the
rare-allele counts to be positively associated with disease
risk (i.e., deleterious) with odds ratios uniformly distrib-
uted from 1.2 to 1.8. Because all risk-associated variants
are associated with risk in the same direction, the simula-
tion is in favor of the burden test. Our EC statistic is based
on the sum of the exponential of squared normal (or chi-
square) statistics and it is not affected by the direction of
association. The simulated data consists of 500 cases and
500 controls. The MAFs of these simulated variants were
sampled uniformly from 0.1% to ~10%. We also repeated
the simulations with MAFs from 0.1% to ~1%, i.e., those
involving only rare and very rare variants. The conclusions
are the same (see Figure S1, available online).
We compared the power of different combination proce-
dures on the basis of two commonly used set-based tests,
the burden test7 and the C-alpha test,10 in three different
scenarios: small genes with ten variants in each gene,
moderately-sized genes with 100 variants, and large genes
with 300 variants. For each scenario, we simulated 1,000
genes. We calculated the gene-level statistics of the burden
test and the C-alpha test, and both were based on the linear
combination of variant statistics. We derived the EC of
these statistics (see Appendix A). We also compared the
original linear combination and the proposed EC with
Tippett’s and Fisher’s combinations on the burden and
the C-alpha statistics. Fisher’s and Tippet’s methods
combine variant-level p values in a gene. In sequencinger 7, 2012
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Figure 2. Power Comparison of the Four Combination Procedures on the Burden Test and the C-alpha Test at the p Value Cutoff
of 0.001
We compared the power of different combination procedures for different gene sizes as the number of risk-associated variants in each
simulated gene increased from 0 to 10. The MAFs of the variants in the simulation range from 0.1% to 10%.studies, the parametric p values for individual variants can
be unreliable as a result of low minor-allele counts for rare
variants. To make a fair comparison, we calculated the
permutation-based p values for individual variants and
then calculated the gene-level statistics for Fisher’s and
Tippet’s methods. Even when based on permutation,
variant-level p values for very rare variants can still be
unreliable, and Fisher’s and Tippet’s methods can suffer
from power losses, especially if rarer variants are more
strongly associated with disease risk. To assess the signifi-
cance of the four combination methods, we calculated
the gene-level p values for each with up to 104 permuta-
tions of phenotypes by using the proposed sequential
precision-improvement permutation method.
Figure 2 shows the power comparison of the four combi-
nation procedures for different gene sizes as the number of
risk-associated variants in each simulated gene increases
from 0 to 10. The p value cutoff is 0.001 (other thresholds
yield similar conclusions). EC is always more powerful
than Tippet’s method, especially when the number of
risk-associated variants in a gene is less sparse, e.g., in small
genes. Linear combination and Fisher’s method are more
powerful than EC in detecting small genes whenmost vari-
ants (R5 out of 10) are associated with disease risks. To
detect moderately sized or large genes, the linear combina-The Americantion of burden statistics is not powerful if only a small
number of variants are associated with disease risk
(Figure 2A). This is because a few risk-associated variants
are combined linearly with a large number of nonassoci-
ated variants, and the overall signal strength is diluted.
The linear combination of C-alpha statistics still has
some power (Figure 2B) but is much less powerful than
the EC of C-alpha statistics, especially for large genes
with 300 variants. For large genes, EC is always more
powerful than competing methods. In practice, with the
availability of whole-genome sequencing, the number of
variants in a gene can be larger than 300, and the EC proce-
dure can be quite useful.
The burden test and the C-alpha test are chosen as exam-
ples because in large samples, they can be approximated by
a linear combination of normal and chi-square statistics,
respectively. In this simulation, as a result of limited
sample size and low MAFs of some variants, many variant
statistics might not be normal or chi-square distributed.
Nevertheless, we still see power improvement from EC
when the number (or proportion) of risk-associated vari-
ants is relatively small. This indicates that violation of
normal or chi-square distribution assumptions does not
invalidate our claim—EC is powerful against a sparse
alternative.Journal of Human Genetics 91, 977–986, December 7, 2012 981
Table 1. Power Comparison of the Four Combination Procedures
at Different p Value Cutoffs
p Value
Cutoff
Linear
Combination EC
Tippett’s
Method
Fisher’s
Method
0.001 0.186 0.266 0.191 0.169
0.005 0.270 0.381 0.286 0.252
0.010 0.326 0.450 0.349 0.306
0.050 0.496 0.636 0.538 0.484
The results are based on a simulation with genotype data from 60 CEU samples
from the 1000 Genomes Project and simulated continuous phenotypes. The
following abbreviation is used: EC, exponential combination.Comparing the Four Combination Procedures on
Simulations Based on Genotype Data from the 1000
Genomes Project
To evaluate the performance of different combination
procedures for dependent variants, we conducted simula-
tions based on the whole-genome sequencing data of the
60 HapMap CEU (Utah residents with ancestry from
northern and western Europe from the CEPH collection)
samples from the 1000 Genomes Project.22 In our simula-
tions and the data analyses that followed, we assigned vari-
ants within the start and end coordinates of a gene as the
variants of the gene. There were 9,390 genes with at least
two variants. The median, mean, and maximum gene sizes
were 61, 168.4, and 19,817 variants, respectively. We
compared the four combination procedures for combining
variant score statistics (or p values of variant score tests) in
the genes. The score statistic for variant i is calculated as
qi ¼ ð
P
jgijyjÞ2, where gij is the rare-allele count for variant
i in individual j and yj is the standardized phenotype for
individual j. Linear combination of variant score statistics
in a gene is formed as
P
jciqi, where ci is the weight for qi
and is inversely proportional to the SD of the score statistic
for variant i under the null. Except for the weighting
scheme, the linear combination of score statistics is equiv-
alent to SKAT with a weighted linear kernel.11 The EC of
score statistics is
P
iexpðð1=2Þ ciqiÞ. Because the SDs of
score statistics for rare variants are smaller than those for
common variants, rarer variants are weightedmore. Single-
tons within a gene are collapsed. Fisher’s and Tippett’s
statistics are calculated on the basis of permutation-based
variant-level p values in the genes. We first simulated
a continuous phenotype under the null, i.e., no gene or
variant is associated with the simulated phenotype. For
each method, we calculated the gene-level p values for
the 9,390 genes with 1,000 permutations. The p values
for all methods were uniformly distributed under the
null (see Figure S2).
To compare the power under sparse alternatives with
dependence, we simulated one continuous phenotype
for each gene in the data and simulated the phenotypes
to be associated with one to four independent variants in
a gene (larger genes were more likely to harbor more causal
variants). The log odds ratios were simulated to be propor-982 The American Journal of Human Genetics 91, 977–986, Decembtional to 1=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
MAF
p
of the variants. Although only up to four
independent causal variants were simulated for each gene,
the actual number of phenotype-associated variants could
be much larger than four, especially for larger genes, as
a result of strong LD among variants in a gene. Table 1
shows the power comparison of the four procedures at
different p value cutoffs. EC is 20%–30% more powerful
than Tippett’s method. This is possibly because depen-
dence among variants reduces the level of sparsity in the
alternative, and by considering statistics other than the
maximum (or p values other than the minimum), EC can
gain additional power. An alternative explanation is that
we simulated rarer variants to be more strongly associated
with phenotype and that the p values for very rare variants
are less reliable, and as such, Tippett’s method based on
individual variant p values can suffer from loss of power.
Even with LD among variants, the alternative is still sparse,
and EC can be 30%–50% more powerful than either
Fisher’s or the linear method.
Application to Cell-Based Pharmacogenomics
In previously reported cell-based pharmacogenomics
studies, cell lines that had been derived from HapMap
CEU samples were treated with platinating agents and
assayed for cellular susceptibility phenotypes.23 In our
study, we focused on two platinating agents: carboplatin
and cisplatin. The platinating agents are some of the
most commonly used chemotherapeutic drugs and are
often used clinically against a wide variety of cancers,
including head-and-neck cancer (MIM 275355), ovarian
cancer (MIM 167000), lung cancer (MIM 211980), and
colorectal cancer (MIM 114500).24 Platinum-based treat-
ment can be accompanied by intrinsic and acquired resis-
tance, but the molecular mechanism of resistance is not
well understood. Translationally, there is an urgent need
for a reliable approach to identifying patients at risk for
significant toxicities.25 Cell-based studies have shown
that pharmacologic phenotypes in the platinating agents
are heritable traits.26 With extensive genotypic (from
the HapMap Project) and whole-genome sequence (from
the 1000 Genomes Project) data,1,22 pharmacogenomic
studies of lymphoblastoid cell lines have facilitated the
investigation of potential genetic etiologies. Investigators
have sought to characterize the role of genetic variation
in conferring platinum-induced cytotoxicity and in the
development of platinum resistance.27
In this study, the half-maximal inhibitory concentration
(IC50) was used for measuring the growth-inhibition effect
of two anticancer drugs, carboplatin and cisplatin. Specifi-
cally, IC50 of carboplatin (or cisplatin) measures the dose of
carboplatin (or cisplatin) needed for inhibiting the cells by
50%. Out of the 60 CEU samples (from the 1000 Genomes
Project) from which genotype data are available, 58 of
them have available (from previous studies23,28,29) the
log2-transformed IC50 of both carboplatin and cisplatin,
and the two cytotoxicity phenotypes are significantly
correlated (correlation ¼ 0.487).er 7, 2012
A B Figure 3. Scatter Plots of p Values Based
on Linear Combination Tests and p Values
Based on EC in the Analyses of Carbopla-
tin and Cisplatin
(A) Carboplatin.
(B) Cisplatin.To identify genes associated with the log2 IC50 of carbo-
platin, and separately with the log2 IC50 of cisplatin, we
formed gene statistics by the linear combination and the
EC of score statistics of variants within a gene. We calcu-
lated p values by permuting the phenotypes by using the
proposed computationally efficient permutation algo-
rithm (see Material and Methods). Because the sample
size in this study was limited and because ~30% of the vari-
ants had five or fewer rare-allele counts in this data, the
individual variant p values could be unreliable even
when they were calculated on the basis of permutation.
Results from Fisher’s and Tippett’s methods based on
combining variant-level p values are therefore not pre-
sented in this analysis.
Figures 3A and 3B show the scatter plots of the p values
by linear-combination tests and the p values by EC in the
analyses of the two drugs, carboplatin and cisplatin,
respectively. Genes with small p values by linear-combina-
tion tests always have small EC p values. In contrast, genes
with small EC p values might not be identified by linear-
combination tests. These plots show that EC is more
powerful than linear-combination tests in both carbopla-
tin and cisplatin analyses. At different p value cutoffs, EC
often yields more significant findings than do linear-
combination tests (see Table S1).
To facilitate further insights into the underlying mecha-
nism of resistance, we conducted DAVID (Database for
Annotation, Visualization and Integrated Discovery) func-
tional enrichment analyses30 on the top 100 EC-identified
genes associated with carboplatin and cisplatin. The top
100 genes associated with carboplatin showed a highly
significant enrichment: 29 genes were involved in acetyla-
tion and had a Benjamini-Hochberg-adjusted p value of
0.0076. It has been reported that acetylation might inter-
fere with resistance mechanisms of chemotherapeutic
agents such as carboplatin and might elevate the activity
of the drug.31,32 Some other pathways, such as blood-
group antigens, phosphoproteins, and transmembrane
proteins, are also significantly enriched with the top genes
from EC in the DAVID functional analyses. In contrast,
only the blood-group-antigen pathway is significantly en-
riched with the top genes from linear combination in the
DAVID functional analyses.The American Journal of Human GenIdentified Susceptibility Loci
Enable Hypotheses onMechanism
of Toxicities
Two claudin-family genes, namely
CLDN9 and the adjacent CLDN6,
show suggestive evidence of associa-tion with both carboplatin and cisplatin log2 IC50.
Claudins are integral membrane proteins that are compo-
nents of tight junction strands. Given that potentially
permanent hearing loss is one of the devastating toxicities
associated with the platinum compounds, both the role of
the claudin-9 gene as essential for hearing in mice studies
and the high sequence conservation of the gene between
mice and humans33 are noteworthy. On the basis of
the EC analysis, the p values for CLDN9 are 0.00085 in
cisplatin (ranked fourth among 9,390 genes) and 0.0015
in carboplatin (ranked 16th); the p values for CLDN6 are
0.00072 (ranked third) and 0.0012 (ranked tenth) for
cisplatin and carboplatin, respectively. Ototoxicity is
much more frequent in cisplatin than in carboplatin,34
consistent with our finding that both genes are slightly
more significant in cisplatin than in carboplatin. On the
basis of the linear-combination analysis, the p values of
the two genes are very close to those of EC but have slightly
worse rankings. These two adjacent genes harbor 14 vari-
ants, mostly with MAFs R 5%, and rare-allele counts of
most variants are negatively correlated with log2 IC50 of
both cisplatin and carboplatin. This suggests that rare
alleles or mutations in claudins might confer sensitivity to
the two platinating agents, consistent with the previous
finding thatwild-type claudin-9 is required for thepreserva-
tion of sensory cells in the hearing organ.33 Figure 4A
displays the association and LD plot35 of the 14 variants
in the two genes. Although none of the variants has an
individual variant p value that reaches genome-wide signif-
icance, several variants (whether in LD or not) are sugges-
tively associated with carboplatin and cisplatin. These re-
sults potentially implicateCLDN9 as a platinumbiomarker.
Another gene, cadherin-2 (CDH2 [MIM 114020]), is
highly significant with a p value of 0.0007 (ranked second)
for cisplatin and a p value of 0.038 for carboplatin by
EC. CDH2 is also known as neural cadherin (NCAD) and
is a calcium-dependent cell-cell adhesion glycoprotein.
The protein is commonly present in cancer cells and has
an important function in transendothelial migration.
Remarkably, in a genome-wide transcriptional study of
genes with significantly altered expression between carbo-
platin-sensitive (S) and carboplatin-resistant (R) cells,
CDH2 was found to have nearly 143 lower expression inetics 91, 977–986, December 7, 2012 983
A B Figure 4. Individual Variant Association
to Platinating Agents and LD Plots
(A) The 14 SNPs in CLDN9 and CLDN6 on
chromosome 8. From left to right, the first
five SNPs are in CLDN9 and the other nine
are in CLDN6.
(B) The 585 SNPs in CDH2 on chromo-
some 10.R cells than in S cells.36,37 Figure 4B displays the associa-
tion and LD plot35 of all variants in the genes. Among
the 585 variants, rare-allele counts of 461 and 419 variants
are negatively correlated with log2 IC50 of cisplatin and
carboplatin, respectively. Except for a few variants with
individual SNP p values below 104, most are not signifi-
cantly associated with either drug. In contrast, this gene
is not significant by linear-combination analysis.Discussion
We propose an EC procedure that sums the exponential of
variant statistics in a gene- or set-based test. We provide
theoretical support for the proposed procedure from both
Bayesian and frequentist perspectives, as well as empirical
evidence via simulated and real application examples,
showing that EC is powerful for detecting sparse alterna-
tives. EC is a general and flexible framework that can be
used for improving power for many existing methods for
set-based analysis of sequencing data. Furthermore, the
proposed procedure is applicable not only to sequencing
data but also to GWAS data or other settings where risk-
associated genetic factors are sparse.
EC is presented here as a gene- or set-based method. In
principle, it is applicable to analyses of pathways, gene-
gene or gene-environment interactions, or other much
larger sets of genomic features. The extensions of EC to
the latter settings might require additional development.
For example, in a pathway, there are specific correlation
structures among variants in a gene and variants between
genes. By treating a pathway as a larger set of variants,
one can lose the advantage of pathway analysis. Further-
more, when a pathway becomes too large (say, with more
than 10,000 variants) and the risk-associated variants in
a pathway are too sparse, even EC might not be powerful
in detecting them. For pathway analysis in association
studies, Yu et al. (2009)18 and Biernacka et al. (2012)19
applied combinationmethods to gene-level p values. Alter-
natively, a mixture of EC and other methods at the gene
and SNP levels might be useful.984 The American Journal of Human Genetics 91, 977–986, December 7, 2012Application of the proposed
approach to the pharmacogenomics
of platinum compounds (specifically,
carboplatin and cisplatin), widely
used for the treatment of various
cancers, has revealed mechanistic
insights underlying resistance andtoxicity. The EC analysis identifies more significance
than does linear combination at most p value thresholds
and implicates shared genetic mechanisms influencing
the drug effects of the two chemotherapeutic agents,
which are often interchangeably used. In addition, results
based on EC recapitulate earlier findings that found
potential connections between cell adhesion and the
development of chemoresistance.37 Our study identified
platinum-associated genes previously shown to be impor-
tant for hearing loss (a devastating toxicity associated
with these compounds) in animal studies.
There might be other situations in which multiple very
rare variants in a set are associated with disease risk and
in which each of them is only weakly associated with
risk. If more than half of the variants in a set are risk asso-
ciated, the alternative hypothesis is different from the
sparse alternative discussed in this work. EC with the
proposed form might not be most powerful in those situa-
tions. On the basis of preliminary exploration, other forms
of EC statistics might offer good power for combining
multiple very rare variants. For example, the EC statistic
of the form
P
expðwiZiÞ, when Zi is normally distributed,
was proposed by van Zwet and Oosterhoff (1967)20 for the
combination of multiple one-sided tests. This form of EC
of burden statistics is very powerful when one combines
multiple very rare variants with the same direction of asso-
ciation with disease risk (e.g., multiple singletons, double-
tons, or tripletons with deleterious rare alleles). However,
for combining only a small number of risk-associated rare
and common variants, the power of
P
expðwiZiÞ is slightly
lower than the power of the proposed EC statistic,P
expðwiZ2i Þ, where Zi is normally distributed.
One caveat of the current EC procedure is that it does not
directly incorporate the potential dependence structure
among variant statistics, which could have complicated
effects on the combined statistic. To circumvent the need
to estimate the dependence structure for rare variants
and properly control the type-I-error rate, we proposed a
sequential precision-improvement permutation algorithm
to obtain p values. Although permutation-based strategies
are often computationally demanding, the proposed
algorithm permutes as few as 100 times for the majority of
the genes (or sets). This algorithm is not only computa-
tionally efficient but also accounts for the potential effect
of the different number of variants in different sets.
With rapid advances in next-generation-sequencing
technologies, many studies are conducting association
analyses between disease risk and whole-exome or
whole-genome sequencing data. Set-based methods have
become more and more widely utilized for identifying
genetic risk factors associated with various disease traits.
The identified genetic factors, especially the rare ones,
could be used for improving our understanding of disease
etiology and for developing personalized approaches to
disease prevention and treatment.
Appendix A
EC for the Burden Test
The burden statistic by Madsen and Browning (2008)
collapses genetic burdens (weighted rare-allele counts) in
cases. The burden test contrasts the burden statistics in
cases versus controls and can be shown to be nearly equiv-
alent to rejection for extreme S ¼Pki¼1si= ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃnfið1 fiÞp ;
where fi is theMAF in controls and si is the rare-allele count
for the ith variant in cases. The burden test is also equiva-
lent to rejecting large normalized statistic S0 ¼Pki¼1s0i ¼Pk
i¼1ðsi  2nfiÞ=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2nfið1 fiÞ
p
, where s0i is the standardized
variant statistic and 2n is the total number of alleles in
cases. We propose the EC of the burden statistic as
~S ¼
Xk
i¼1
exp

1
2
s02i

:EC for the C-alpha Test
The C-alpha test statistic is defined as T ¼Pki¼1ti and
ti ¼ ðsi  vigÞ2  vigð1 gÞ, where si is the rare-allele count
for variant i in cases, vi is the total rare-allele count for
variant i in all samples, and g is the proportion of cases
among all samples; each variant statistic ti contrasts the
variance of observed rare-allele counts in cases with ex-
pected variance and tests for overdispersion of variant i.
It can be seen that the original C-alpha statistic linearly
combines the test statistic from each variant. We propose
the EC of the C-alpha statistic as
~T ¼
Xk
i¼1
exp

1
2
t 0i

;
where t 0i is a weighted variant statistic, t
0
i ¼ citi. We propose
the weight ci to be inversely proportional to the SD of ti
under the null, where the SD can be estimated by permuta-
tion. Because statistics of rarer variants have smaller SDs,
rarer variants are weighted more in the combination test.
Supplemental Data
Supplemental Data include two figures and one table and can be
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